plerixafor has been researched along with Sarcoma, Ewing in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berning, P; Clemens, D; Dirksen, U; Korsching, E; Potratz, J; Schaefer, C | 1 |
| Hamdan, R; Kleinerman, ES; Zhou, Z | 1 |
| Aksu, T; Demir, HA; Emir, S; Kara, A; Özgüner, M; Tunç, B | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Lanza, F; Lemoli, R; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Almazán, F; Grifols, JR; Juncà, J; Ribera, JM; Sancho, JM; Vives, S | 1 |
1 trial(s) available for plerixafor and Sarcoma, Ewing
| Article | Year |
|---|---|
Use of plerixafor for peripheral blood stem cell mobilization failure in children.
Topics: Adolescent; Adult; Anti-HIV Agents; Autografts; Benzylamines; Child; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Male; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Sarcoma, Ewing | 2014 |
4 other study(ies) available for plerixafor and Sarcoma, Ewing
| Article | Year |
|---|---|
The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Topics: Benzylamines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotaxis; Cyclams; Enzyme Activation; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Receptors, CXCR4; Sarcoma, Ewing; Signal Transduction | 2018 |
Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors.
Topics: Animals; Benzylamines; Blotting, Western; Bone Marrow Cells; Bone Marrow Transplantation; Cell Differentiation; Cell Line, Tumor; Cell Survival; Chemokine CXCL12; Cyclams; Down-Regulation; Female; Heterocyclic Compounds; Humans; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Fluorescence; Neovascularization, Pathologic; Pericytes; Proto-Oncogene Proteins c-sis; Receptors, CXCR4; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2014 |
European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Blood Component Removal; Bone Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclams; Europe; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Sarcoma, Ewing; Stem Cell Transplantation; Wiskott-Aldrich Syndrome; Young Adult | 2012 |
Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma.
Topics: Adolescent; Antigens, CD34; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Peripheral Blood Stem Cell Transplantation; Sarcoma, Ewing; Treatment Outcome | 2012 |